Product Name :
FT827
Description:
FT827 is a selective and covalent ubiquitin-specific protease 7 (USP7) inhibitor (Ki=4.2 µM). FT827 binds to the USP7 catalytic domain (USP7CD; residues 208-560) with an apparent Kd value of 7.8 µM.
CAS:
1959537-86-0
Molecular Weight:
548.61
Formula:
C27H28N6O5S
Chemical Name:
N-4′-[4-hydroxy-4-(1-methyl-4-oxo-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-5-ylmethyl)piperidine-1-carbonyl]-[1,1′-biphenyl]-2-ylethene-1-sulfonamide
Smiles :
CN1N=CC2=C1N=CN(CC1(O)CCN(CC1)C(=O)C1C=CC(=CC=1)C1=CC=CC=C1NS(=O)(=O)C=C)C2=O
InChiKey:
GFNJQQBUZURQMA-UHFFFAOYSA-N
InChi :
InChI=1S/C27H28N6O5S/c1-3-39(37,38)30-23-7-5-4-6-21(23)19-8-10-20(11-9-19)25(34)32-14-12-27(36,13-15-32)17-33-18-28-24-22(26(33)35)16-29-31(24)2/h3-11,16,18,30,36H,1,12-15,17H2,2H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.Methotrexate web
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.Lipopolysaccharides Purity & Documentation
Additional information:
FT827 is a selective and covalent ubiquitin-specific protease 7 (USP7) inhibitor (Ki=4.2 µM). FT827 binds to the USP7 catalytic domain (USP7CD; residues 208-560) with an apparent Kd value of 7.8 µM.|Product information|CAS Number: 1959537-86-0|Molecular Weight: 548.61|Formula: C27H28N6O5S|Chemical Name: N-4′-[4-hydroxy-4-(1-methyl-4-oxo-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-5-ylmethyl)piperidine-1-carbonyl]-[1,1′-biphenyl]-2-ylethene-1-sulfonamide|Smiles: CN1N=CC2=C1N=CN(CC1(O)CCN(CC1)C(=O)C1C=CC(=CC=1)C1=CC=CC=C1NS(=O)(=O)C=C)C2=O|InChiKey: GFNJQQBUZURQMA-UHFFFAOYSA-N|InChi: InChI=1S/C27H28N6O5S/c1-3-39(37,38)30-23-7-5-4-6-21(23)19-8-10-20(11-9-19)25(34)32-14-12-27(36,13-15-32)17-33-18-28-24-22(26(33)35)16-29-31(24)2/h3-11,16,18,30,36H,1,12-15,17H2,2H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 125 mg/mL (227.PMID:31992031 85 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|FT827 features a vinylsulfonamide moiety that covalently modifies the catalytic Cys223 of USP7 and inhibits the enzyme with Ki and Kd of 4.2 and 7.8 μM, respectively. FT827 exclusively inhibit USP7 in a panel of 38 deubiquitinases (DUBs) from diverse families. FT827 inhibits USP7 probe reactivity with IC50s of 0.1-2 µM, confirming 10 to 100-fold higher potency as compared to P22077 in crude cell extracts or with intact MCF7 breast cancer cells, followed by incubation with the ubiquitin active site suicide probe haemagglutinin (HA)-tagged ubiquitin bromoethyl (HA-UbC2Br).|References:|Turnbull AP, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature. 2017 Oct 26;550(7677):481-486.Products are for research use only. Not for human use.|
